Therapeutic and Adverse Effect of Anti-PD1 Immunotherapy in Melanoma: A Retrospective, Single-Institute Study of 222 Patients.

Grethe EikenesGabriella LiszkayTímea BalatoniKata CzirbeszKaren HunyadiZsófia KozékiMihály Tamás KispálFanni BaranyaiTímea DanyiKatalin BőcsIstván Kenessey

Published in: Cancers (2023)

Although the range of immunotherapeutic options is getting wider, in the management of melanoma patients, anti-PD1 monotherapy remains an important, effective, and safe method. However, significant correlation was found between the immune-related side effects and therapeutic efficacy.

Keyphrases

end stage renal disease
newly diagnosed
chronic kidney disease
prognostic factors
clinical trial
combination therapy
patient reported outcomes